コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 hepatitis in wildtype (WT), perforin(-/-) , tumor necrosis factor related apoptosis inducing ligand
2 Tumor necrosis factor related apoptosis-inducing ligand
3 were also more resistant to chemotherapy and tumor necrosis factor-related apoptosis inducing ligand
4 Six1 overexpression renders OCC resistant to tumor necrosis factor-related apoptosis inducing ligand
5 Tumor necrosis factor-related apoptosis inducing ligand
6 Tumor necrosis factor-related apoptosis inducing ligand
7 a secretable variant of the cytotoxic agent tumor necrosis factor-related apoptosis inducing ligand
8 lignant B cells were relatively resistant to tumor necrosis factor-related apoptosis inducing ligand
9 moter and found POX-stimulated expression of tumor necrosis factor-related apoptosis inducing ligand
10 of combining the apoptosis-inducing protein tumor necrosis factor-related apoptosis inducing ligand
11 NDA-expressing K562 clones were resistant to tumor necrosis factor-related apoptosis inducing ligand
12 ed by granzyme B, IFN-gamma, and Apo2 ligand/tumor necrosis factor-related apoptosis inducing ligand
13 While tumor necrosis factor-related apoptosis inducing ligand
14 Tumor necrosis factor-related apoptosis inducing ligand
15 itive to the combination of the death ligand tumor necrosis factor-related apoptosis inducing ligand
16 Reovirus-induced apoptosis is mediated by tumor necrosis factor-related apoptosis inducing ligand
17 Apo2L/TRAIL (tumor necrosis factor-related apoptosis inducing ligand
18 Tumor necrosis factor-related apoptosis inducing ligand
19 ty in individual cells following exposure to tumor necrosis factor-related apoptosis-inducing ligand
20 fatty acid binding protein, calcitonin, and tumor necrosis factor-related apoptosis-inducing ligand
21 c protein FLIP(S), and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand
22 Tumor necrosis factor-related apoptosis-inducing ligand
23 4(-)CD8(-) T-lymphocyte apoptosis and plasma tumor necrosis factor-related apoptosis-inducing ligand
24 The proapoptotic cytokine tumor necrosis factor-related apoptosis-inducing ligand
25 he expression of apoptotic receptors FAS and tumor necrosis factor-related apoptosis-inducing ligand
26 e secondary CD8+ T cell responses because of tumor necrosis factor-related apoptosis-inducing ligand
27 these, recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand
28 The ligation of tumor necrosis factor-related apoptosis-inducing ligand
29 The contribution of tumor necrosis factor-related apoptosis-inducing ligand
30 D8/caspase-8, paclitaxel, or paclitaxel plus tumor necrosis factor-related apoptosis-inducing ligand
31 ) CML cells had higher surface expression of tumor necrosis factor-related apoptosis-inducing ligand
32 ng cell surface levels of DR5, and augmented tumor necrosis factor-related apoptosis-inducing ligand
33 g to the induction of Bax, Bim, DR4/DR5, and tumor necrosis factor-related apoptosis-inducing ligand
34 Tumor necrosis factor-related apoptosis-inducing ligand
35 Tumor necrosis factor-related apoptosis-inducing ligand
36 ic recipients of donor BM deficient in Fas-, tumor necrosis factor-related apoptosis-inducing ligand
37 We report that clinically relevant levels of tumor necrosis factor-related apoptosis-inducing ligand
38 The regulation of tumor necrosis factor-related apoptosis-inducing ligand
39 enetically modified to express surface-bound tumor necrosis factor-related apoptosis-inducing ligand
40 apoptosis elicited by DNA-damaging drugs and tumor necrosis factor-related apoptosis-inducing ligand
41 apoptotic stimuli, including combinations of tumor necrosis factor-related apoptosis-inducing ligand
42 Tumor necrosis factor-related apoptosis-inducing ligand
43 Bcl-2 family members inhibit the ability of tumor necrosis factor-related apoptosis-inducing ligand
44 atment of infected cells with the OPG ligand tumor necrosis factor-related apoptosis-inducing ligand
45 -5 promotes apoptosis upon signaling through tumor necrosis factor-related apoptosis-inducing ligand
46 Tumor necrosis factor-related apoptosis-inducing ligand
47 Tumor necrosis factor-related apoptosis-inducing ligand
48 One such agent is the tumor necrosis factor-related apoptosis-inducing ligand
49 Tumor necrosis factor-related apoptosis-inducing ligand
50 n that PS-341 induces apoptosis and enhances tumor necrosis factor-related apoptosis-inducing ligand
51 Tumor necrosis factor-related apoptosis-inducing ligand
52 inant adenovirus encoding full-length murine tumor necrosis factor-related apoptosis-inducing ligand
53 orylated galectin-3 (P-GAL3) into GAL3-null, tumor necrosis factor-related apoptosis-inducing ligand
54 y investigated DMC's cooperative effect with tumor necrosis factor-related apoptosis-inducing ligand
55 in levels and sensitized the cancer cells to tumor necrosis factor-related apoptosis-inducing ligand
56 Here, we show that 5-aza-CdR induces tumor necrosis factor-related apoptosis-inducing ligand
57 ceptibility of melanoma cells to recombinant tumor necrosis factor-related apoptosis-inducing ligand
58 nduced apoptosis appeared to be triggered by tumor necrosis factor-related apoptosis-inducing ligand
59 ween the multikinase inhibitor sorafenib and tumor necrosis factor-related apoptosis-inducing ligand
60 ls, and this was accompanied by induction of tumor necrosis factor-related apoptosis-inducing ligand
61 Tumor necrosis factor-related apoptosis-inducing ligand
62 Tumor necrosis factor-related apoptosis-inducing ligand
63 efitinib did interact with recombinant human tumor necrosis factor-related apoptosis-inducing ligand
64 er lysosomal permeabilization contributes to tumor necrosis factor-related apoptosis-inducing ligand
65 , and natural killer (NK) cell expression of tumor necrosis factor-related apoptosis-inducing ligand
66 Tumor necrosis factor-related apoptosis-inducing ligand
67 Tumor necrosis factor-related apoptosis-inducing ligand
68 te death receptor 5 (DR5) and cooperate with tumor necrosis factor-related apoptosis-inducing ligand
69 his vector also expresses adenovirus E1A and tumor necrosis factor-related apoptosis-inducing ligand
70 Tumor necrosis factor-related apoptosis-inducing ligand
71 tic proteins were previously found to reduce tumor necrosis factor-related apoptosis-inducing ligand
72 l, increased apoptosis, and sensitization to tumor necrosis factor-related apoptosis-inducing ligand
73 ffect the sensitivity of human astrocytes to tumor necrosis factor-related apoptosis-inducing ligand
74 indicated that the proapoptotic genes BNIP3, tumor necrosis factor-related apoptosis-inducing ligand
75 lly, IFN-alpha induced a 10-fold increase of tumor necrosis factor-related apoptosis-inducing ligand
76 of 2-methoxyestradiol and Fas ligand (FasL)/tumor necrosis factor-related apoptosis-inducing ligand
77 IFN induced tumor necrosis factor-related apoptosis-inducing ligand
78 in induction of apoptosis and enhancement of tumor necrosis factor-related apoptosis-inducing ligand
79 as antibody but not apoptosis induced by the tumor necrosis factor-related apoptosis-inducing ligand
80 Blocking NKG2D or tumor necrosis factor-related apoptosis-inducing ligand
81 merase-cleavage and caspase-3 activity after tumor necrosis factor-related apoptosis-inducing ligand
82 ombining LBW242 with novel agents, including tumor necrosis factor-related apoptosis-inducing ligand
83 s associated with up-regulation of p53, Bax, tumor necrosis factor-related apoptosis-inducing ligand
84 ers in our laboratory observed expression of tumor necrosis factor-related apoptosis-inducing ligand
85 appreciated, especially the emerging role of tumor necrosis factor-related apoptosis-inducing ligand
86 tion of TRAIL induces acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand
87 erforin, and granzyme B, and expressed CD69, tumor necrosis factor-related apoptosis-inducing ligand
88 a, intercellular adhesion molecule (ICAM)-1, tumor necrosis factor-related apoptosis-inducing ligand
89 ls and increased the expression of NKG2D and tumor necrosis factor-related apoptosis-inducing ligand
90 icant increase in surface expression of DR5 [tumor necrosis factor-related apoptosis-inducing ligand
91 otect cells from apoptosis induced either by tumor necrosis factor-related apoptosis-inducing ligand
92 Tumor necrosis factor-related apoptosis-inducing ligand
93 gulation of the decoy receptor that inhibits tumor necrosis factor-related apoptosis-inducing ligand
94 Tumor necrosis factor-related apoptosis-inducing ligand
95 effects of reactive oxygen species (ROS) on tumor necrosis factor-related apoptosis-inducing ligand
96 activation of cell surface receptors by the tumor necrosis factor-related apoptosis-inducing ligand
97 by blocking antibodies against TNFalpha and tumor necrosis factor-related apoptosis-inducing ligand
98 Tumor necrosis factor-related apoptosis-inducing ligand
99 on sensitizes human colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand
100 lective, proapoptotic, death receptor ligand tumor necrosis factor-related apoptosis-inducing ligand
101 vation of the death receptor (DR) pathway by tumor necrosis factor-related apoptosis-inducing ligand
102 tress protein HSP70 in turn induced membrane tumor necrosis factor-related apoptosis-inducing ligand
103 ription 1 (STAT1), phosphorylated STAT1, and tumor necrosis factor-related apoptosis-inducing ligand
104 ome of the ADAM family members, enhances the tumor necrosis factor-related apoptosis-inducing ligand
105 s are normally resistant to apoptosis, Apo2L/tumor necrosis factor-related apoptosis-inducing ligand
106 Decoy receptor 2 (DcR2) is one of the tumor necrosis factor-related apoptosis-inducing ligand
107 Tumor necrosis factor-related apoptosis-inducing ligand
108 mia-2 family, is an important participant in tumor necrosis factor-related apoptosis-inducing ligand
109 Tumor necrosis factor-related apoptosis-inducing ligand
110 When given with tumor necrosis factor-related apoptosis-inducing ligand
111 tate of the NF-kappaB pathway in response to tumor necrosis factor-related apoptosis-inducing ligand
112 Using tumor necrosis factor-related apoptosis-inducing ligand
113 induction of cell death pathways, including tumor necrosis factor-related apoptosis-inducing ligand
114 an apoptosis-inducing membrane receptor for tumor necrosis factor-related apoptosis-inducing ligand
115 Tumor necrosis factor-related apoptosis-inducing ligand
116 Tumor necrosis factor-related apoptosis-inducing ligand
117 Tumor necrosis factor-related apoptosis-inducing ligand
118 duced to undergo apoptosis by treatment with tumor necrosis factor-related apoptosis-inducing ligand
119 Tumor necrosis factor-related apoptosis-inducing ligand
120 Tumor necrosis factor-related apoptosis-inducing ligand
121 Tumor necrosis factor-related apoptosis-inducing ligand
122 Although tumor necrosis factor-related apoptosis-inducing ligand
123 Tumor necrosis factor-related apoptosis-inducing ligand
124 Tumor necrosis factor-related apoptosis-inducing ligand
125 Although the tumor necrosis factor-related apoptosis-inducing ligand
126 nts indicated that OPG formed a complex with tumor necrosis factor-related apoptosis-inducing ligand
127 L) and XIAP) and cooperates with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand
128 ducible p53-regulated death receptor for the tumor necrosis factor-related apoptosis-inducing ligand
129 e we investigated the effects of IFNalpha on tumor necrosis factor-related apoptosis-inducing ligand
130 llular pH (pHe) promotes cell killing by the tumor necrosis factor-related apoptosis-inducing ligand
131 As compared with treatment with Apo-2L/tumor necrosis factor-related apoptosis-inducing ligand
132 Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand
133 Tumor necrosis factor-related apoptosis-inducing ligand
134 red mouse NPCs to deliver a secreted form of tumor necrosis factor-related apoptosis-inducing ligand
135 eptor (DR) 4 or 5, on binding to its ligand, tumor necrosis factor-related apoptosis-inducing ligand
136 Tumor necrosis factor-related apoptosis-inducing ligand
137 d two purposes: to examine the expression of tumor necrosis factor-related apoptosis-inducing ligand
138 poptosis, especially on apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand
139 The death receptor ligand Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand
140 eversed resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand
141 Many tumor cell types are sensitive to tumor necrosis factor-related apoptosis-inducing ligand
142 tin abolished both cycloheximide-induced and tumor necrosis factor-related apoptosis-inducing ligand
143 Here, we show that the tumor necrosis factor-related apoptosis-inducing ligand
144 itor (camptothecin, topotecan, or SN-38) and tumor necrosis factor-related apoptosis-inducing ligand
145 Death receptor 4 (DR4) is one of the tumor necrosis factor-related apoptosis-inducing ligand
146 Tumor necrosis factor-related apoptosis-inducing ligand
147 tosis-inducing ligand 2 (Apo2L), also called tumor necrosis factor-related apoptosis-inducing ligand
148 s have shown CpG oligodeoxynucleotide induce tumor necrosis factor-related apoptosis-inducing ligand
149 6 potentiated the activity of apoliprotein 2/tumor necrosis factor-related apoptosis-inducing ligand
150 tion strongly up-regulated the expression of tumor necrosis factor-related apoptosis-inducing ligand
151 hway, induction of the proapoptotic mediator tumor necrosis factor-related apoptosis-inducing ligand
152 he resistance of neuroblastoma (NB) cells to tumor necrosis factor-related apoptosis-inducing ligand
153 o the cytotoxic activities of the DR5 ligand tumor necrosis factor-related apoptosis-inducing ligand
154 gene expression showed temporal increases in tumor necrosis factor-related apoptosis-inducing ligand
155 nate effector cells in the liver and express tumor necrosis factor-related apoptosis-inducing ligand
156 Tumor necrosis factor-related apoptosis-inducing ligand
157 However, OPG can block tumor necrosis factor-related apoptosis-inducing ligand
158 Tumor necrosis factor-related apoptosis-inducing ligand
159 Tumor necrosis factor-related apoptosis-inducing ligand
160 uate the apoptotic response to the cytotoxic tumor necrosis factor-related apoptosis-inducing ligand
161 ant to treatment with Apo2 ligand (Apo2L) or tumor necrosis factor-related apoptosis-inducing ligand
162 agents etoposide and mitomycin C but not by tumor necrosis factor-related apoptosis-inducing ligand
163 reports have suggested that the death ligand tumor necrosis factor-related apoptosis-inducing ligand
164 Tumor necrosis factor-related apoptosis-inducing ligand
165 transformed cells, inhibit transcription of tumor necrosis factor-related apoptosis-inducing ligand
166 Tumor necrosis factor-related apoptosis-inducing ligand
167 c oxide (NO) and increases the expression of tumor necrosis factor-related apoptosis-inducing ligand
168 Tumor necrosis factor-related apoptosis-inducing ligand
169 Tumor necrosis factor-related apoptosis-inducing ligand
170 Tumor necrosis factor-related apoptosis-inducing ligand
171 Tumor necrosis factor-related apoptosis-inducing ligand
172 he death-receptor ligand apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand
173 EL cells, the death receptor ligand known as tumor necrosis factor-related apoptosis-inducing ligand
174 Tumor necrosis factor-related apoptosis-inducing ligand
175 expression modulates apoptosis induction by tumor necrosis factor-related apoptosis-inducing ligand
176 of specific death receptors with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand
177 d the resulting cancer cell death induced by tumor necrosis factor-related apoptosis-inducing ligand
178 adenocarcinoma DU-145 cells were exposed to tumor necrosis factor-related apoptosis-inducing ligand
179 steoprotegerin (OPG) is a decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand
180 Here we show that tumor necrosis factor-related apoptosis-inducing ligand
181 n their quiescent phenotypes to apoptosis by tumor necrosis factor-related apoptosis-inducing ligand
182 Tumor necrosis factor-related apoptosis-inducing ligand
183 sensitivity to the death ligand Apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand
184 and -3, are most homologous to those of the tumor necrosis factor-related apoptosis-inducing ligand
185 e major concern for use of recombinant human tumor necrosis factor-related apoptosis-inducing ligand
186 tosis by up-regulation of gene expression of tumor necrosis factor-related apoptosis-inducing ligand
187 biopharmaceutical proteins recombinant human tumor necrosis factor-related apoptosis-inducing ligand
188 We replaced GFP with tumor necrosis factor-related apoptosis-inducing ligand
189 cells paradoxically express the death ligand tumor necrosis factor-related apoptosis-inducing ligand
190 th agonists of two distinct death receptors, tumor necrosis factor-related apoptosis-inducing ligand
191 ivation of IRF5 by the death receptor ligand tumor necrosis factor-related apoptosis-inducing ligand
192 Although tumor necrosis factor-related apoptosis-inducing ligand
193 Tumor necrosis factor-related apoptosis-inducing ligand
194 Tumor necrosis factor-related apoptosis-inducing ligand
195 otein, triggers apoptosis upon ligation with tumor necrosis factor-related apoptosis-inducing ligand
196 w that ENb primes GBM cells for proapoptotic tumor necrosis factor-related apoptosis-inducing ligand
197 s and expressed cytotoxic molecules, such as tumor necrosis factor-related apoptosis-inducing ligand
198 Tumor necrosis factor-related apoptosis-inducing ligand
199 tic, fully human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand
200 6-activating receptor in the face of reduced tumor necrosis factor-related apoptosis-inducing ligand
201 We have previously reported tumor necrosis factor-related apoptosis-inducing ligand
202 nuclear factor-kappaB ligand/osteoprotegerin/tumor necrosis factor-related apoptosis-inducing ligand
203 ell surface pro-apoptotic death receptor for tumor necrosis factor-related apoptosis-inducing ligand
204 her histone deacetylase (HDAC) inhibitors or tumor necrosis factor-related apoptosis-inducing ligand
205 by cisplatin, irradiation, recombinant human tumor necrosis factor-related apoptosis-inducing ligand
206 we additionally noticed upregulation of the tumor necrosis factor-related apoptosis-inducing ligand
207 MUC16-knockdown breast cancer cells through Tumor necrosis factor-related apoptosis-inducing ligand
208 Tumor necrosis factor-related apoptosis-inducing ligand
209 Tumor necrosis factor-related apoptosis-inducing ligand
210 cytotoxicity, measured by degranulation and tumor necrosis factor-related apoptosis-inducing ligand
211 previous studies have revealed that acquired tumor necrosis factor-related apoptosis-inducing ligand
212 Hepatocyte-derived EVs contained tumor necrosis factor-related apoptosis-inducing ligand
213 f IFN-gamma-inducible protein-10 (IP-10) and tumor necrosis factor-related apoptosis-inducing ligand
214 Tumor necrosis factor-related apoptosis-inducing ligand
215 nclude an agonist for the apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand
216 demonstrate varying levels of sensitivity to tumor necrosis factor-related apoptosis-inducing ligand
217 ells paradoxically express the death ligand, tumor necrosis factor-related apoptosis-inducing ligand
218 One impediment to the use of tumor necrosis factor-related apoptosis-inducing ligand
219 Apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand
220 Tumor necrosis factor-related apoptosis-inducing ligand
221 CAS expression itself is up-regulated during tumor necrosis factor-related apoptosis-inducing ligand
222 activator of nuclear factor kappaB axis and tumor necrosis factor-related apoptosis-inducing ligand
223 Tumor necrosis factor-related apoptosis-inducing ligand
224 totic protein FLIP(S) is a key suppressor of tumor necrosis factor-related apoptosis-inducing ligand
225 es in the presence of AMAs markedly increase tumor necrosis factor-related apoptosis-inducing ligand
226 ng a hepatocyte-specific promoter, and adeno-tumor necrosis factor-related apoptosis-inducing ligand
227 ome dichotomy in the role of OPG, RANKL, and tumor necrosis factor-related apoptosis-inducing ligand
228 ant cancer cells to apoptosis in general and tumor necrosis factor-related apoptosis-inducing ligand
229 ocarcinoma (CCA) cells paradoxically express tumor necrosis factor-related apoptosis-inducing ligand
230 human sarcoma cells to both FasL-induced and tumor necrosis factor-related apoptosis-inducing ligand
231 caspase-8 axis, and is strongly enhanced by tumor necrosis factor-related apoptosis-inducing ligand
232 lly-human agonist monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand
233 late BID, DR5, and p73, become sensitized to tumor necrosis factor-related apoptosis-inducing ligand
234 ious observations demonstrated that acquired tumor necrosis factor-related apoptosis-inducing ligand
235 that MSCs engineered to produce and deliver tumor necrosis factor-related apoptosis-inducing ligand
236 oxO proteins and their proapoptotic targets, tumor necrosis factor-related apoptosis-inducing ligand
237 ency of natural killer (NK) cells expressing tumor necrosis factor-related apoptosis-inducing ligand
238 inger, can enhance the anticancer effects of tumor necrosis factor-related apoptosis-inducing ligand
239 ptosis by various chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand
240 M) kinase on the regulation of the extrinsic tumor necrosis factor-related apoptosis-inducing ligand
241 e-derived stem cells (hADSCs) overexpressing tumor necrosis factor-related apoptosis-inducing ligand
242 BCG stimulated the release of tumor necrosis factor-related apoptosis-inducing ligand
243 target, as well as sensitizing CCA cells to tumor necrosis factor-related apoptosis-inducing ligand
244 Tumor necrosis factor-related apoptosis-inducing ligand
245 vitro, bortezomib-treated tumors had higher tumor necrosis factor-related apoptosis-inducing ligand
246 It was further manifested that tumor necrosis factor-related apoptosis-inducing ligand
247 l, a dietary triterpene, on (a) apoptosis of tumor necrosis factor-related apoptosis-inducing ligand
248 f IFN-beta (IFNbeta), granzyme A (GRZA), and tumor necrosis factor-related apoptosis-inducing ligand
249 While it is well established that tumor necrosis factor-related apoptosis-inducing ligand
250 Although tumor necrosis factor-related apoptosis-inducing ligand
251 Tumor necrosis factor-related apoptosis-inducing-ligand
252 ated the expression of the DR5 ligand TRAIL (tumor necrosis factor-related apoptosis inducing ligand)
253 pha) and express the apoptotic ligand TRAIL (tumor necrosis factor-related apoptosis inducing ligand)
254 TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)
255 sage for TNFalpha, Fas ligand (FasL), TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)
256 tosis initiation by Apo2L/TRAIL (Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand)
257 Here, we show that a physiological signal (tumor necrosis factor-related apoptosis-inducing ligand)
258 r family of apoptotic receptors (FAS, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)
259 The cytotoxic death ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)
260 The death ligand, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)
261 Finally, injection of anti-TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)
262 p-regulation by ATO of R1 and R2 APO2/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)
263 shown that the death receptor ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)
264 Apo-2L/TRAIL (tumor-necrosis factor-related apoptosis-inducing ligand)
265 ced natural killer group 2 member D (NKG2D), tumor necrosis factor-related apoptosis-inducing ligand,
266 ignant cells to tumor necrosis factor alpha, tumor necrosis factor-related apoptosis-inducing ligand,
267 h receptor ligands, including Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand,
268 or (FAS), FASL, FAS-associated death domain, tumor necrosis factor-related apoptosis-inducing ligand,
269 -stimulating factor, but not perforin (Pfp), tumor necrosis factor-related apoptosis-inducing ligand,
270 In response to tumor necrosis factor-related apoptosis-inducing ligand,
271 ession of death receptor ligands, CD95-L and tumor necrosis factor-related apoptosis-inducing ligand,
272 the tumor necrosis factor family (Fas/FasL, tumor necrosis factor-related apoptosis-inducing ligand,
273 ected protease 3 (caspase-3), interleukin-2, tumor necrosis factor-related apoptosis-inducing ligand,
274 TRAIL, the tumor necrosis factor-related apoptosis-inducing ligand,
275 s, because blocking antibodies for TNFalpha, tumor necrosis factor-related apoptosis-inducing ligand,
276 s enzyme because when they were treated with tumor necrosis factor-related apoptosis-inducing ligand,
277 increased resistance to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand,
278 et-unidentified mechanism not requiring Fas, tumor necrosis factor-related apoptosis-inducing ligand,
279 nodules showed reactivities to antibodies to tumor necrosis factor-related apoptosis-inducing ligand,
280 or-kappaB ligand and the proapoptotic factor tumor necrosis factor-related apoptosis-inducing ligand,
281 ng chemokine, monokine induced by IFN-gamma, tumor necrosis factor-related apoptosis-inducing ligand,
282 -delivery of a membrane-associated cytokine (tumor-necrosis-factor-related apoptosis-inducing ligand,
283 otype, and assists TRXR1-regulated arrest of tumor necrosis factor-related apoptosis-inducing ligand-
284 ion leads to sensitization to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-
285 cell-surface DR5 distribution, and enhanced tumor necrosis factor-related apoptosis-inducing ligand-
286 c acid early inducible 1/NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-
287 ster, which blocks Notch signaling, enhanced tumor necrosis factor-related apoptosis-inducing ligand-
288 sed by C4-2 cells protected these cells from tumor necrosis factor-related apoptosis-inducing ligand-
289 itor-mediated "priming to death" facilitates tumor necrosis factor-related apoptosis-inducing ligand-
290 noculated human glioblastoma xenografts with tumor necrosis factor-related apoptosis-inducing ligand-
291 threshold sensitized neuroblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand-
292 tage to tumor cells and resistance to innate tumor necrosis factor-related apoptosis-inducing ligand-
293 to Fas at certain concentrations but not to tumor necrosis factor-related apoptosis-inducing ligand.
294 i-Fas antibody, Fas ligand, irradiation, and tumor necrosis factor-related apoptosis-inducing ligand.
295 ppressive mechanism that can be activated by tumor necrosis factor-related apoptosis-inducing ligand.
296 ensitized the cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand.
297 of IL-15 is mediated through upregulation of tumor necrosis factor-related apoptosis-inducing ligand.
298 ) and a trend toward increased production of tumor necrosis factor-related apoptosis-inducing ligand.
299 of nuclear factor kappaB ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand.
300 y CD8(+) T cells lacked expression of TRAIL (tumor necrosis factor-related apoptosis-inducing ligand;
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。